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Abstract
This study aimed at evaluating the relative contribution of endothelial cyclooxygenase-1 and -2 (COX-1 and COX-2) to
prostacyclin (PGI2) production in the presence of mild oxidative stress resulting from autooxidation of polyphenols such as
(-)-epigallocatechin 3-gallate (EGCG), using both endothelial cells in culture and isolated blood vessels. EGCG treatment
resulted in an increase in hydrogen peroxide formation in human umbilical vein endothelial cells. In the presence of
exogenous arachidonic acid and EGCG, PGI2 production was preferentially inhibited by a selective COX-1 inhibitor. This
effect of selective inhibition was also substantially reversed by catalase. In addition, EGCG caused vasorelaxation of rat aortic
ring only partially abolished by a nitric oxide synthase inhibitor. Concomitant treatment with a selective COX-1 inhibitor
completely prevented the vasorelaxation as well as the increase in PGI2 accumulation in the perfusate observed in EGCG-
treated aortic rings, while a selective COX-2 inhibitor was completely uneffective. Our data strongly support the notions that
H2O2 generation affects endothelial PGI2 production, making COX-1, and not COX-2, the main source of endothelial PGI2
under altered oxidative tone conditions. These results might be relevant to the reappraisal of the impact of COX inhibitors
on vascular PGI2 production in patients undergoing significant oxidative stress.
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Introduction
Arachidonic acid is metabolized by cyclooxygenase (COX)
isoforms to form a number of tissue-specific mediators such as
prostacyclin (PGI2) and thromboxane A2 (TXA2), which represent
functionally antagonistic vasoactive prostanoids regulating several
aspects of vascular biology. There are two main COX isoforms:
COX-1 is constitutively expressed in most tissues and mediates
basal physiological functions, while COX-2 is induced by various
stimuli, such as inflammatory cytokines, thus being mostly
associated with pathological conditions [1].
Although endothelial cells constitutively express COX-1 [2],
there is now a general agreement that PGI2 in vascular
endothelium is generated mainly by COX-2, probably as a result
of COX-2 expression induced by laminar flow shear stress [3].
This finding has assumed a great relevance after the reports of
increased thromboembolic death associated with the use of
COXIBs [4], leading to the hypothesis that the cardiovascular
risk associated with the use of COXIBs is the result of their
selective inhibition of the synthesis of cardio-protective PGI2,
leaving unopposed the platelet-derived, COX-1 dependent, pro-
thrombotic lipid mediator TXA2 [5].
It is widely known that COX enzymes are bi-functional proteins
endowed with both cyclooxygenase (COX) and peroxidase (POX)
activities, and that hydroperoxides are required for the first heme
oxidation at the POX site of the enzyme [6]. Consistently,
biochemical studies of COX activity using purified enzymes
clearly demonstrated that COX-1 requires a higher peroxide tone
than COX-2 to be activated [7], suggesting that hydroperoxide
availability could enhance prostanoid production via COX-1
rather than COX-2. We previously observed that COX isoform
activity in HUVECs resembles that of isolated enzymes, as we
provided evidence that PGI2 production by endothelial cells
undergoing different modalities of oxidative stress is mediated by
COX-1, abundantly expressed by these cells, and not by COX-2
[8]. Although a large body of data suggested that PGI2 production
by endothelium could be positively [9] or negatively [10,11]
affected by free radicals, this evidence was lacking informations on
the relative contribution of COX isoforms to PGI2 production.
Epigallocatechin-3-gallate (EGCG), the main catechin of green
tea, is known to undergo auto-oxidation and generate reactive
oxygen species (ROS) [12], which in turn has been reported it may
cause cytoprotective effects [13] and endothelium-dependent
relaxation [14]. There is no general agreement on the role of
ROS produced by polyphenols in cell culture medium as recently
reviewed [15], however, unpublished data from our laboratory
clearly indicated an increase in ROS production by human
neutrophils treated with a number of grape-derived polyphenols in
phosphate buffer saline solution; additional evidence is available
that EGCG elicits contraction of isolated aorta in hypertensive rats
and this effect is mediated by ROS production, which in turn leads
to vasoconstrictive prostanoid release [16].
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56683
Based on the consideration that ECGC may affect vascular tone
through ROS production, and since endothelial COX activity is
modulated by hydroperoxide tone, we used the ability of EGCG to
generate low concentrations of hydrogen peroxide as a pharma-
cological tool for evaluating the effects of ROS on endothelial
PGI2 production in the presence of selective COX-1 or COX-2
inhibitors, using both isolated HUVECs and ex vivo models of
endothelial function. We found that ROS produced by EGCG
lead to the production of endothelial PGI2 by derived by the
constitutive COX-1 isoform.
Materials and Methods
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of
Health (Bethesda, MD, USA; NIH Publication No. 85-23, revised
1996) and the study was approved by the local Ethic Committee at
the Dipartimento di Scienze Farmacologiche e Biomolecolari.
Animals
Male Sprague-Dawley rats (2 mo old; Charles River, Calco,
Italy), initial weight 200–225 g, were used. The animals were
housed in a conditioned environment (2261uC, 5565% relative
humidity, 12-h light/12-h dark cycle), with free access to standard
laboratory chow and tap water.
Vasorelaxation studies
After anesthesia (Pentotal Sodium, 60 mg.kg21, i.p., Zootec-
nica di S.Donato, MI, Italia), rats were sacrificed by exsanguina-
tion. Thoracic aorta was carefully removed, cleaned of fat and
connective tissue, and cut into 5- to 6-mm rings. Vessels were
suspended in 5-ml organ baths containing Krebs-Henselheit
solution (KHS) at 37uC, continuously bubbled with 95% O2 and
5% CO2. KHS had the following composition (mM): 118 NaCl,
4.7 KCl, 1.2 KH2PO4, 1.1 MgSO4, 2.5 CaCl2, 25 NaHCO3, and
5.5 glucose; pH 7.4. The rings were connected to isometric tension
transducers (Fort 10; World Precision Instruments, Sarasota, FL,
USA) coupled with a digital recording system (PowerLab 8SP;
ADInstruments, Colorado Springs, CO, USA). Vascular tissues
were equilibrated for 30 min and contracted with 1025 M
noradrenalin (NA) to develop a maximal response. Preparations
were then washed with fresh KHS, and the equilibration period
was allowed to continue for a further 30 min. Experiments were
carried out on tissues precontracted with NA to 60% of maximal
contraction (EC60 = 10
27 M). The endothelium was considered
functional because relaxation of precontracted vessels to 1025 M
acetylcholine was $80%. After equilibration, relaxation by
increasing concentrations (0.1–100 mM) of EGCG was performed
to obtain cumulative concentration-response curves. Selected
experiments were performed in rings treated with 100 mM L-
NAME and/or with the selective COX-1 inhibitor SC560
(10 nM) and COX-2 inhibitor SC236 (10 nM) before NA
contraction. All reagents were purchased from Sigma (St Louis,
MO, USA) if not otherwise specified. SC560 was from Cayman
Chemical (Ann Arbor, Michigan, USA) and SC236 was kindly
provided from Searle (St. Louis, MO, USA).
Cell culture
Human umbilical vein endothelial cells (HUVECs) obtained as
previously published [17], were grown in medium 199 (M199,
Invitrogen, S. Giuliano Milanese, Milan, Italy) supplemented with
15% FCS (Euroclone; Pero, Milan, Italy), gentamicin (40 g/ml,
Invitrogen), endothelial cell growth factor (25 g/ml), and heparin
(100 g/ml), at 37uC in a humidified 5% CO2 atmosphere. Cells
were identified as endothelial by their morphology and the
presence of CD31-related antigen. All experiments were per-
formed on cells at the second passage. HUVECs were seeded at
equal density in 6-well plates (36105/well). For experiments, cells
were incubated in M199 supplemented with 5% FCS. Selected
experiments were carried out in the presence of EGCG (1–
100 mM), superoxide dismutase (SOD; 0.2 U/ml), catalase (CAT;
300 U/ml), diphenyleneiodonium chloride (DPI, 1 mM), arachi-
donic acid (10 mM; Cayman Chemical), SC560 (1–100 nM), or
SC236 (1–100 nM). Inhibitors were added 15 min before the
stimulus.
ROS concentration
ROS levels in cells treated with EGCG (10–100 mM) were
determined by flow-cytometry (Beckman Coulter Epics XL Flow
Cytometer) using 29,79-dichlorfluorescein-diacetate (DCFH-DA), a
cell membrane-permeable fluorogenic probe. The acetate groups
of this probe are enzymatically cleaved inside living cells. The
probe can then be oxidized by intracellular oxidants (ROS) to give
a product, DCF, which emits a strong, green fluorescence
(lex = 504 nm; lem= 529 nm). The fluorescence intensity increas-
es in proportion to the level of cellular oxidants and is expressed as
percent increase vs basal values. ECGC ability to spontaneously
release ROS was also tested by incubations in M199 supplemented
with 5% FCS in the presence of the ROS-sensitive probe;
hydrogen peroxide (100 mM), was used as a ROS to induce the
oxidation of the probe. The possibility that AA itself could
spontaneously generate ROS was also tested by incubating
endothelial cells (5–60 min) with AA at different concentrations
(0.1–10 mM), in the absence or presence of EGCG.
Determination of PGI2 production
After incubation, the culture medium or the perfusate of
EGCG-treated aortic were collected and centrifuged at 10,000 g
for 5 min. 6-keto PGF1a, the stable hydrolysis product of PGI2,
was measured with specific EIA kits (Cayman Chemical) according
to the manufacturer’s instructions.
Statistical analysis
Data were obtained from 3 to 6 independent experiments, each
one carried out in duplicate or triplicate determinations.
Comparison between groups was performed by ANOVA followed
by Sheffe`’s test for multiple comparisons. Values of P#0.05 were
considered statistically significant.
Results
ECGC increases hydrogen peroxide production in
HUVECs
In order to evaluate the effect of oxidative stress, HUVECs
grown in medium 199 added with 5% FCS were treated with
increasing concentrations (10–100 mM) of epigallocatechin-3-
gallate for different times (15–60 min) in the presence of DCFH-
DA. EGCG generated an increase in ROS formation, peaking at
100 mm and 30 minutes (Figs. 1A and B). Pre-treatment of
HUVECs with 300 U/ml catalase, the enzyme responsible for
hydrogen peroxide breakdown, abolished the increase in ROS
production triggered by ECGC (Fig. 2). Conversely, treatment of
HUVECs with either the NADPH oxidase inhibitor diphenyle-
neiodonium (DPI; 1 mM)(Fig. 3) or superoxide dismutase (SOD;
0.2 U/ml)(data not shown) did not affect ROS production in the
presence of ECGC, ruling out the involvement of endogenous
enzymatic systems such as NADPH oxidase. Taken together, these
data suggest that short-term treatment with EGCG increases
Mild Oxidative Stress and COX-1 Activity
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oxidant tone in endothelial cells, mostly inducing H2O2 produc-
tion by the molecule itself, independent from NADPH oxidase.
Indeed, when incubated with cells in DPBS, EGCG did not result
in ROS formation in HUVECs, while the simple incubation of
DCFH-DA in cell culture media, in the absence of cells, resulted in
conversion of the probe into the fluorescent, ROS-generated form
(data not shown), confirming that medium and/or FCS compo-
nents are required for EGCG autooxidation [18].
Effect of selective COX-1 and COX-2 inhibitors on the
production of PGI2 in the presence of ECGC in HUVECs
A lower availability of substrates or hydroperoxides may result in
preferential activation of COX-2, whereas an higher ‘‘hydroper-
oxide tone’’ as well as higher arachidonic acid concentrations may
direct the production of COX metabolites through the activity of
COX-1. Because of the effects of EGCG on ROS formation,
resulting in an increased ‘‘hydroperoxide tone’’ within endothelial
cells, we compared the effect of the selective COX-2 inhibitor
SC236 (1–100 nM) and the selective COX-1 inihibitor SC560 (1–
100 nM) on PGI2 production in HUVECs treated with ECGC in
the presence of exogenous arachidonic acid. Exogenous arachi-
donic acid (10 mM) per se caused a modest but significant increase
in ROS formation in endothelial cells. Nevertheless this increase
was negligible when compared to ROS formation associated to the
incubation with EGCG (data not shown). PGI2 formation by
endothelial cells in the presence of AA was indeed significantly
enhanced upon incubation with EGCG, an increase that was
potently and completely inhibited by the COX-1 inhibitor SC560,
while the COX-2 inhibitor SC236 caused a rather limited (about
50%) inhibition of PGI2 production (Fig. 4), at a concentration
(100 nM) 20-fold higher than its reported IC50 for COX-2. In
agreement with the hypothesized role of ECGC-derived hydrogen
peroxide in PGI2 biosynthesis, PGI2 production in HUVECs
treated with ECGC in the presence of catalase was significantly
lower with respect to that observed in the absence of catalase
(0.62660.087 ng/ml ECGC+AA+catalase vs 2.7960.42 ng/ml
ECGC+AA) and was concentration-dependently inhibited by both
SC236 and SC560 within the same range of concentrations (Fig. 5),
suggesting that, as previously published [8], in endothelial cells the
basal production of PGI2 involves both COX-1 and COX-2
activities.
Figure 1. Effect of EGCG on intracellular ROS production. A) HUVECs were treated with EGCG (10, 50, 100 mM) for 30 minutes. B) HUVECs were
treated with EGCG 100 mM for increasing times (15, 30, 60 min). Values are expressed as percentage 6 SE (n = 14, A; n = 5, B) of the amount of ROS
generated under basal conditions. *P,0.05, **P,0.1 vs control.
doi:10.1371/journal.pone.0056683.g001
Figure 2. Effect of catalase on EGCG-induced ROS production.
HUVECs were pre-incubated with catalase (300 U/ml) and treated with
EGCG 100 mM for 30 min. Values are expressed as percentage 6 SE
(n = 3) of the amount of ROS generated under basal conditions. *P,0.05
vs control and #P,0.05 vs cells treated with EGCG.
doi:10.1371/journal.pone.0056683.g002
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Effect of selective COX-1 and COX-2 inhibitors on ECGC-
induced vasodilation in isolated aortic rings
To further explore the possible consequences of ECGC-
produced ROS on the activity of the two cyclooxygenase isoforms
in endothelial cells, we used an ex vivo model of endothelial
function.
As previously reported [19] ECGC induced a concentration-
dependent (0.1–50 mM) vasorelaxation in NA-precontracted aortic
rings that was only partially inhibited by preincubation with L-
NAME (100 mM)(Fig. 6). Concentration-response curves with
EGCG were carried out up to the concentration of 50 mM,
already resulting in a consistent vasorelaxation of .50% in all the
preparations tested. Furthermore, no arachidonic acid was added
to the isolated organ preparations, as arachidonic acid was likely to
be made available by the multicellular environment represented
by the isolated organ undergoing smooth muscle contraction.
Indeed mechanotransduction is known to activate the phospho-
lipase A2 involved in arachidonic acid release [20,21]. In order to
determine if arachidonic acid metabolites were involved in the
ECGC-induced, NO-independent vasorelaxation, tissues were
pretreated with either SC236 or SC560 in the presence of L-
NAME, resulting in the complete inhibition of the response to
ECGC only in the presence of the COX-1 inhibitor SC560
(10 nM) but not of the COX-2 inhibitor SC236 (10 nM),
suggesting a critical involvement of COX-1-derived metabolites
in EGCG-mediated vasorelaxation. In strict agreement with
functional data, EGCG resulted in a significant increase in PGI2
concentrations into the rat aorta perfusate obtained at the end of
the concentration-response experiments, and such increase in the
concentrations of the vasodilating PGI2 was completely prevented
by the pretreatment with SC560 (10 nM) but not by SC236
(Fig. 7).
Discussion
In the present study we provide evidence that, in the presence of
enhanced hydroperoxide tone due to hydrogen peroxide gener-
ation by EGCG, only the selective COX-1 inhibitor SC560, but
not the selective COX-2 inhibitor SC236 impaired endothelial
PGI2 production in intact vessels, suggesting that ROS production
affects endothelium-mediated vasodilation through the production
of COX-1-derived PGI2.
PGI2, the main product of COX in the endothelium, exerts a
variety of beneficial effects on endothelial integrity and function-
ality, acting per se as well as counteracting the pro-thrombotic and
pro-adhesive properties of platelet-derived thromboxane. The
withdrawal from the market of the selective COX-2 inhibitor
rofecoxib after evidence of an increased cardiovascular risk
associated with the use of the drug, fostered research aimed at
understanding the mechanisms underlying the cardiovascular
toxicity of anti-inflammatory drugs. The main accepted hypoth-
esis, recently revised in an editorial on Science [22], is that the
selective inhibition of endothelial COX-2-derived PGI2, leaving
platelet COX-1-derived thromboxane unaffected, was responsible
for the enhanced risk of thromboembolic events in patients treated
with COXIBs. However, this so called ‘‘imbalance theory’’ minimizes
the role of endothelial COX-1, the housekeeping isoform of
cyclooxygenase which is abundantly expressed in endothelial cells.
Because COX-1 and COX-2 activity are differentially regulated
by several factors, such as the availability of substrate (i.e.
arachidonic acid, AA) [23,24,25,26] and/or hydroperoxides [7],
we hypothesized that conditions may occur that alter the relative
contribution of each COX isoform to the overall PGI2 production,
Figure 3. Effect of DPI on EGCG-induced ROS production.
HUVECs were pre-incubated with DPI 1 mM and treated with EGCG
100 mM for 30 min. Values are expressed as percentage 6 SE (n = 3) of
the amount of ROS generated under basal conditions. *P,0.05 vs
control and #P,0.05 vs cells treated with EGCG.
doi:10.1371/journal.pone.0056683.g003
Figure 4. Effect of treatment with selective COX-1 (SC560) or
COX-2 (SC236) inhibitors toward PGI2 production in HUVECs
incubated with EGCG. Cells were incubated in medium 5% FCS in the
presence of increasing concentrations of SC560 or SC236 (1–100 nM);
10 min after treatment with inhibitors, cells were added with
arachidonic acid (10 mM) and EGCG (100 mM) for 30 min. PGI2 was
evaluated as 6-keto-PGF1a in aliquots of cell supernatants using a
specific EIA. Values are expressed as pg/ml 6 SE (n= 3) of 6-keto-PGF1a.
# P,0.01 vs AA alone; *P,0.05, **P,0.01 vs. (AA+EGCG).
doi:10.1371/journal.pone.0056683.g004
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and we previously reported that, in the presence of exogenous
arachidonic acid and hydroperoxides (12-HpETE) or in co-
cultures with activated platelets providing an endogenous source of
12-HpETE [8], PGI2 production by endothelial cells appears to be
mediated mainly by COX-1 and not by COX-2. Based on these
observations, with the present study we further explored the
possible role of oxidative stress on PGI2 production using EGCG
autooxidation as a mild source of intracellular oxidative stress,
mimiking long lasting oxidative stress in inflamed tissues, both in
cultured human endothelial cells and in an ex-vivo model of
endothelial function. Indeed EGCG might undergo auto-oxida-
tion and may be a source of reactive oxygen species (ROS) [12],
and ROS generation by EGCG, at concentrations similar to those
used in our study, have been reported to contribute to
cytoprotective effects [13] as well as endothelium-dependent
relaxation [14]. More recently, Auger et al. [27] demonstrated
that ROS from EGCG induce endothelium-dependent NO-
mediated relaxation of coronary artery rings through Akt-
dependent activation of eNOS, but the real contribution of
ROS to the long-term in vitro effects of polyphenols [18] is still
under debate.
It must be stressed that epigallocatechin gallate (EGCG) in our
study was used at high concentration only to take advantage of its
low level of spontaneous intracellular generation of reactive
oxygen species together with its extremely low cellular toxicity,
and our data confirmed that ECGC resulted in ROS formation
within human endothelial cells, but it is difficult that there may be
therapeutic implications about this kind of activity of EGCG,
given the high concentrations required. In the present study, the
only reactive oxygen species formed after treatment of human
endothelial cells with EGCG was hydrogen peroxide, since
catalase, but not superoxide dismutase, was able to abrogate
EGCG-generated ROS. While a simple incubation of EGCG in
tissue colture media generated a low and long lasting production of
Figure 5. Effect of treatment with selective COX-1 (SC560) or
COX-2 (SC236) inhibitors toward PGI2 production in HUVECs
incubated with EGCG, in the presence of catalase. Cells were
incubated in medium 5% FCS in the presence of increasing
concentrations of SC560 or SC236 (1–100 nM); 10 min after treatment
with inhibitors, cells were treated with catalase (300 U/ml) for 15 min.
Afterward, arachidonic acid (10 mM) and EGCG (100 mM) were added for
30 min. PGI2 was evaluated as 6-keto-PGF1a in aliquots of cell
supernatants using a specific EIA. Values are expressed as pg/ml 6 SE
(n=3) of the 6-keto-PGF1a. #P,0.01 vs (EGCG+AA); *P,0.05 and
**P,0.01 vs. (EGCG+AA+catalase).
doi:10.1371/journal.pone.0056683.g005
Figure 6. Vasorelaxing response to EGCG in the presence of
selective COX-1 and COX-2 inhibitors in intact rat aortic rings.
Increasing concentrations of EGCG were added to tissues pre-
contracted with 10 mM NA and preincubated with L-NAME 100 mM
alone or in the presence of either the selective COX-2 inhibitor SC236
10 nM or the selective COX-1 inhibitor SC560 10 nM. # P,0.01
(EGCG+L-NAME) vs (EGCG); * P,0.01 (EGCG+L-NAME+SC560) vs
(EGCG+L-NAME).
doi:10.1371/journal.pone.0056683.g006
Figure 7. PGI2 production in perfusate from aortic rings treated
with EGCG in the presence of selective COX-1 and COX-2
inhibitors. Samples from EGCG-treated aortic rings preincubated with
L-NAME alone or in the presence of either the selective COX-2 inhibitor
SC236 or the selective COX-1 inhibitor SC560 were collected and PGI2
was evaluated as 6-keto-PGF1a. Values are expressed as pg/ml of
perfusate. uP,0.01 vs L-NAME; *P,0.01 vs (EGCG+L-NAME); #P,0.01 vs
(EGCG+L-NAME+SC560).
doi:10.1371/journal.pone.0056683.g007
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ROS, the NADPH inhibitor DPI did not decrease ROS
production in EGCG-treated cells, confirming that oxidative
enzyme activation was not involved in ROS formation by EGCG.
In line with studies using purified COX enzymes that indicate a
differential sensitivity of COX isoforms to hydroperoxide activa-
tion, with COX-1 activation requiring higher peroxide concen-
tration than COX-2, we demonstrated that in the presence of
EGCG COX-1 is the main isoform responsible for PGI2
production by the endothelium. Indeed, in HUVEC challenged
with EGCG the selective COX-1 inhibitor SC560 resulted more
potent and effective than the selective COX-2 inhibitor SC236 in
inhibiting PGI2 production. On the contrary, in the presence of
catalase suppressing the mild oxidation induced by EGCG, both
SC236 and SC560 negatively affected the residual production of
PGI2 with similar potency and efficacy, suggesting that COX-1
becomes the main isoform responsible for endothelial PGI2
production only under conditions of increased hydroperoxide
availability such as with EGCG or, pathophysiologically, in the
presence of increased oxidative stress such as in diabetes or in the
presence of activated platelets. In further agreement with these
results, in a well-established ex vivo model of endothelial function,
we demonstrated that EGCG up to 50 mM induced a concentra-
tion-dependent vasodilation, which was partially mediated by
PGI2 and blocked by the selective COX-1 inhibitor SC560 but not
by the COX-2 selective SC236. The determination of the
hydrolysis product of PGI2 in the isolated organ superperfusion
buffer at the end of the concentration-response curves with EGCG
also showed increased concentrations of vasodilating PGI2 when
compared to control isolated vessels that were not exposed to
EGCG. The increase in PGI2 concentrations resulting from
EGCG was inhibited by pretreatment with the COX-1 selective
inhibitor SC560 only, but not by COX-2 selective inhibition. The
results we obtained with ECGC may therefore improve our
understanding of the effects of cyclooxygenase inhibitors (both
COXIBs and traditional NSAIDs) on endothelial cells as these
cells appear to change their ability to synthesize the vasoprotective
PGI2 as a result of COX-1 and/or COX-2 activity depending on
the presence of oxidative stress and hydrogen peroxide. Moreover,
we describe for the first time a possible link between hydrogen
peroxide-mediated vasodilation and PGI2, a result consistent with
the notion that COX enzymes are bi-functional proteins endowed
with both cyclooxygenase (COX) and peroxidase (POX) activities,
and that hydroperoxides are required for the first heme oxidation
at the POX site of the enzyme [6].
Overall, these findings also provide new insights into the
homeostatic mechanisms of the endothelium responses to ROS
and H2O2 and support COX-1 as the main source of endothelial
PGI2 under altered oxidative tone conditions, suggesting that it
might be important to reappraise the impact of cyclooxygenase
inhibitors on vascular PGI2 production in patients undergoing
significant oxidative stress.
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